explore -WSS

explore

author：knowledge 2025-10-01 11:46:20 - browse：72

Sarepta - Cambridge -AP — Kristoffer Tripplaar/Sipa via AP

To hear Sarepta CEO Doug Ingram tell it, the results Monday afternoon from a large trial of its gene therapy for Duchenne muscular dystrophy marked a clear medical breakthrough. “A massive win,” he told investors, that could lead to its approval for all patients with the fatal muscle-wasting disease regardless of age.

And yet the rest of the Duchenne community was more cautious in its enthusiasm. The study — the most rigorous test to date of a technology 30 years in the making — had technically failed, as so many had before it.

“It’s extremely frustrating,” said John Brandsema, a pediatric neurologist at Children’s Hospital of Philadelphia who worked on the study. “When you spend decades trying to bring therapies into the clinic for something so severe and just keep missing over and over again.”

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Walensky prepares to leave CDC — and Congress — behind
Next article： There should be a 'Moonshot' or 'Warp Speed' for rare diseases

entertainment

WSS

Indian pharmaceutical industry in denial over drug

Key lawmaker blasts Congress’ efforts on addiction: ‘Shame on us’

Are embryos people? Reproductive medicine's future depends on the answer

EF3 tornado rips through North Carolina amid extreme weather nationwide

Study identifies new proteins linked to dementia risk 25 years later

Readout Newsletter: Beam, Prozac, "TechBio" and more

focus

explore

Wikipedia

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

Elisabeth Bik tackles the widespread issue of research misconduct

Medical leaders decry Supreme Court decision on affirmative action

Readout Newsletter: Beam, Prozac, "TechBio" and more

Moonlake's readout produced a cash windfall. Risks remain

Cholera vaccine supplies dangerously low, outbreaks surging

Activists slam private health insurers over coverage restrictions

'Stay indoors': Escaped wild animal on the loose in Berlin prompts urgent citywide search

Psychedelics group wrestles with new pharma identity

Judge rejects Trump's request to move Stormy Daniels hush

knowledge

Indian pharmaceutical industry in denial over drug

Cholera vaccine supplies dangerously low, outbreaks surging

DeSantis talks Trump, trans issues and 'what wokeness is'

Readout Newsletter: Beam, Prozac, "TechBio" and more

A Q&A with Gavi’s Seth Berkley on vaccines, Covid, and more

Readout Newsletter: GSK, Viking Therapeutics, mifepristone news

entertainment

knowledge

hotspot

hotspot